Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Advanced Cancer × BMS-813160 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 1 Colorectal Neoplasms 1 Advanced Cancer 1

Interventions

Nivolumab 7 linrodostat 3 Ipilimumab 3 relatlimab 2 Pemetrexed 2 tislelizumab 1 regorafenib 1 ralimetinib 1 p38 Mitogen-Activated Protein Kinases 1 figitumumab 1 efatutazone 1 abemaciclib 1 Vorinostat 1 Tamoxifen 1 Sunitinib 1 Ranitidine 1 Midazolam 1 LY2603618 1 LY2584702 1 Gemcitabine 1 Fulvestrant 1 Dasatinib 1 Crizotinib 1 Cetuximab 1 Carboplatin 1 BMS-813160 1 3-(9-fluoro-2-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydro(1,4)diazepino(6,7,1-hi)indol-7-yl)-4-imidazo(1,2-a)pyridin-3-yl-1H-pyrrole-2,5-dione 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02996110 2022-12-19

FRACTION-RCC

Bristol-Myers Squibb

Phase 2 Completed

182 enrolled 23 charts

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡